Vivity Study in Taiwan
A Prospective Study of Vivity & Vivity Toric IOL in Taiwan: Results and Analysis
1 other identifier
observational
100
1 country
1
Brief Summary
The aim of study is to evaluate the quality of vision after bilateral Vivity or Vivity toric EDOF IOLs implantation in Taiwan.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Dec 2022
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 15, 2022
CompletedFirst Submitted
Initial submission to the registry
November 10, 2024
CompletedFirst Posted
Study publicly available on registry
December 6, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2024
CompletedDecember 6, 2024
December 1, 2024
2 years
November 10, 2024
December 5, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Visual acuity (LogMAR)
Uncorrected binocular far, intermediate and near visual acuity. Corrected binocular far, intermediate and near visual acuity.
From enrollment to the end of treatment at 3 months
Other Outcomes (1)
Intermediate reading speed (seconds)
From enrollment to the end of treatment at 3 months
Study Arms (1)
Vivity/Vivity toric
Eligibility Criteria
Patients who intended for sequential bilateral cataract surgery and implanted with Vivity/Vivity IOL would be asked to include in this study.
You may qualify if:
- Patients with age-related cataract requiring surgery treatment
- Patient who received bilateral, uneventful implantation of Vivity IOLs
- Patient's IOL power is between 10-30D, and T2-T6 for toric correction
- Cataract grade 0\~3 based on the Wisconsin cataract grading system
You may not qualify if:
- Cataract grade 4\~5 based on the Wisconsin cataract grading system
- Patient's IOL power is outside of 10-30D or T2-T6 for toric correction
- Patient with the following ocular comorbidities:
- Corneal opacities or irregularities;
- Severe dry eye;
- Amblyopia;
- Glaucoma;
- Non-dilating pupil;
- History of intraocular surgery, laser therapy, or retinopathy;
- Optic nerve or macular diseases;
- Uncontrolled diabetic mellitus or systemic immune disease;
- Refusal or unable to maintain follow-up
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Taiwan Nobel Eye Clinic
Taipei, Taiwan
Related Publications (2)
Kandavel R, Colvard M, Dredge J, Bayle M, Alam T, Snyder J, Hall B. Comparative Study Between Non-Diffractive Extended Depth of Focus and Monofocal Intraocular Lenses. Clin Ophthalmol. 2023 Apr 14;17:1161-1168. doi: 10.2147/OPTH.S402069. eCollection 2023.
PMID: 37082300RESULTHovanesian JA, Jones M, Allen Q. The Vivity Extended Range of Vision IOL vs the PanOptix Trifocal, ReStor 2.5 Active Focus and ReStor 3.0 Multifocal Lenses: A Comparison of Patient Satisfaction, Visual Disturbances, and Spectacle Independence. Clin Ophthalmol. 2022 Jan 18;16:145-152. doi: 10.2147/OPTH.S347382. eCollection 2022.
PMID: 35082481RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
ChaoKai Chang, Ph.D.
Taiwan Nobel Eye Clinic
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Doctor
Study Record Dates
First Submitted
November 10, 2024
First Posted
December 6, 2024
Study Start
December 15, 2022
Primary Completion
December 31, 2024
Study Completion
December 31, 2024
Last Updated
December 6, 2024
Record last verified: 2024-12
Data Sharing
- IPD Sharing
- Will not share